Engrail Therapeutics

Precision Neuroscience. Transformational Therapies.

San Diego, United States · Founded 2019 · $221.0M raised

Employees
11–50
Founded
2019
Business Model
B2B
Total Funding
$221.0M
Last Round
$157.0M Series BMar 2024
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Engrail Therapeutics is a clinical-stage pharmaceutical company focused on developing precision-targeted neuroscience therapies for neuropsychiatric and neurodevelopmental diseases. Its pipeline includes ENX-102 (GABA-A PAM for generalized anxiety disorder) and ENX-104 (for major depressive disorder with anhedonia), both in Phase 2 trials. The company raised a $157M Series B in 2024 to advance its programs.

Summary

Engrail Therapeutics is a Biotech company based in San Diego, United States, founded in 2019. It has raised $221.0M in total across 3 rounds, most recently a $157.0M Series B round in Mar 2024. Investors include F-Prime Capital, Forbion Capital Partners and Norwest Venture Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BMar 2024
$157.0M

Sign up to see all 3 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Engrail Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/engrail-therapeutics"><img src="https://indexed.vc/api/badge/company/engrail-therapeutics" alt="Engrail Therapeutics on Indexed.vc" width="260" height="76" /></a>